Aims/Hypothesis: Bariatric surgery is currently employed as an effective approach to treat class III obesity and class II obesity with co-morbidities. Unfortunately, the general anthropometric and metabolic outcomes of the surgery are not homogeneous, and defining the eligibility criteria that allow for a more precise prediction of the outcomes of this invasive procedure will refine the selection of patients. Here we tested the hypothesis that the Gly482Ser polymorphism of the ppargc1a gene would predict different outcomes following bariatric surgery. Methods: Fifty-five patients (26 Gly/Gly and 29 Gly/Ser þ Ser/Ser) selected for the Roux-en-Y gastric bypass according to the National Institutes of Health Consensus Statement criteria were followed up for 1 year, monitoring their anthropometric, metabolic and inflammatory parameters. Results: Patients with the Gly482Ser polymorphism had significantly improved reductions in the waist/hip ratio, fasting blood glucose, C-reactive protein, blood leukocyte count, serum interleukin-6 and intima-media thickness of the carotid artery, as compared with Gly/Gly patients. Conclusions/Interpretation: Thus, the Gly482Ser polymorphism may predict a more favorable metabolic and inflammatory outcome for obese patients submitted to bariatric surgery, leading to a reduced atherosclerotic risk.
Introduction
Obesity affects more than 300 million people in the world, and these numbers are predicted to increase to more than 1 billion by the year 2030. 1 Most patients are refractory to behavioral and pharmacological approaches, undergoing no more than 10-15% of body mass reduction, which is usually followed by a partial or complete relapse. 2, 3 Recent studies have shown that the massive and more stable body-mass reduction provided by bariatric surgery has a positive impact on cardiovascular mortality, and thus, the number of patients being selected for this modality of treatment is rapidly increasing. 4 A major problem with the current selection criteria for bariatric surgery is that many of the anthropometric and metabolic outcomes achieved following the intervention are heterogeneous, and no specific markers or factors predicting the best outcomes are known. 5 The identification of such parameters would optimize the selection of patients and increase the rate of success of the surgery. PGC1a is a co-activator of transcription involved in the regulation of several metabolic and non-metabolic functions, ranging from thermogenesis and hepatic glucose production to heme and cytokine expression. 6 A number of recent studies have shown the association of the most common ppargc1a (gene coding for PGC1a) polymorphism, the Gly482Ser, with diseases such as type 2 diabetes, hypertension, hypercholesterolemia and obesity. [7] [8] [9] However, no previous study has evaluated the association of this polymorphism with the outcomes of bariatric surgery. Here, we tested the hypothesis that the Gly482Ser polymorphism of the ppargc1a gene could predict some clinical and laboratorial outcomes, and also a structural atherosclerotic surrogate marker, that is, carotid intimamedia thickness (C-IMT), of bariatric surgery. The evaluation of 55 patients revealed that the Gly482Ser polymorphism was significantly associated with improved reductions in the waist/hip ratio, blood glucose, ultra-sensitive C-reactive protein (us-CRP), blood leukocyte count, serum interleukin-6 (IL-6) and carotid IMT (C-IMT).
Materials and methods

Subjects
Patients (n ¼ 55, female ¼ 47) were selected for the Roux-en-Y gastric bypass based on the National Institutes of Health Consensus Statement criteria for bariatric surgery. Criteria for selection of patients were as follows: inclusion: men and women between 18 and 60 years of age who met the abovementioned criteria for surgery; and exclusion: inflammatory or infectious disease, use of psychotropic or anti-inflammatory drugs, and history of substance abuse or addiction. As a whole, 22% of the selected patients had the diagnosis of type 2 diabetes mellitus. Clinical evaluation and determination of anthropometric, C-IMT, metabolic and inflammatory parameters were performed at baseline, at 1, 6 and 12 months after the intervention. The study was approved by the University of Campinas Ethics Committee, and all the patients signed an informed consent form.
Detection of the Gly482Ser polymorphism
The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was performed using the following primers: ) was administered. Fasting glycemia was maintained (variation o5%) by a variable-rate glucose infusion, and blood glucose determination (glucose oxidase) was done every 5 min by using a YSI 2700 biochemistry analyzer (Yellow Springs Inc., Yellow Springs, OH, USA). If fasting hyperglycemia was present, it was corrected to a target of 100 mg dl À1 by the initial intravenous insulin infusion.
Insulin sensitivity index was calculated as the glucose infusion rate in the last 60 min (steady state), corrected for the glucose distribution space and adjusted to fat-free mass, yielding the M value. Other indices of insulin sensitivity index were calculated from the M value: glucose metabolic clearance rate (MCRg ¼ M/steady-state glycemia) and M adjusted for steady-state insulin (M/I).
Carotid Doppler studies
The carotid scans were performed by two independent observers using an ultrasonography device (Vivid 3, GE Healthcare, Waukesha, WI, USA) with a linear array probe 10L H40412LG (4-11 MHz), according to a method previously published. 10 The IMT was measured 1 cm distal to the bulbus, over a 1-cm length of both carotid arteries. Measurements in three different locations on the far wall were taken, and the maximum value was taken for each carotid artery. The final C-IMT was obtained from the average of the right and left carotid arteries.
Statistical analysis
Data were analyzed by three distinct methods. The intragroup over-time variations, and the intra-group differences between baseline and 12-month values were analyzed by the Wilcoxon signed-rank test. The inter-group over-time variations were analyzed by the Mann-Whitney test. In addition, for some parameters, mean differences between baseline and 12-month values were analyzed by the Student's t-test.
Results
At baseline, all the analyzed parameters were statistically similar between the groups (Tables 1-3) . At 12 months after surgery, the body mass index had dropped from 45 to 28 kg m À2 in the patients of the Gly/Gly group, and from 44 to 28 kg m À2 in the patients of the Gly/Ser þ Ser/Ser group (Table 1) . These changes were statistically significant in the intra-group analysis and were similar in the inter-group analysis (Table 1) . Regarding the anthropometric parameters, PGC1a polymorphism in obesity SR Geloneze et al a 12-month follow-up was accompanied by significant intra-group changes in waist, hip and neck circumferences, systolic and diastolic blood pressure, and fat mass in both groups (Table 1 ). There was a significant reduction in the waist/hip ratio only in the Gly/Ser þ Ser/Ser group and, upon comparison of means of reductions, there was a significant difference between the groups (Figure 1a ). 
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The blood levels of total cholesterol, HDL, LDL and triglycerides dropped significantly after 12 months in both groups, and no significant differences were detected for these parameters in the inter-group analysis (Table 2) . Free-fatty acids underwent no significant changes either in the intra-or in the inter-group analysis during the 12-month follow-up (Table 2) . Interestingly, blood glucose levels dropped significantly only in the Gly/Ser þ Ser/Ser group, and this resulted in a significant difference between the groups (Table 2 and Figure 1b) . The remaining parameters related to blood glucose regulation, namely, insulin, HbA1c, homeostatic model assessment-insulin resistance and the hyperinsulinemic-euglycemic clamp, underwent significant changes only in the intra-group, but not in the inter-group analysis (Table 2) . Similarly, leptin, adiponectin and visfatin showed significant changes during the 12-month follow-up only in the intra-, but not in the inter-group analysis (Table 2 ). In addition, resistin underwent no significant changes during the 12-month follow-up in either group, and this was accompanied by no significant differences in the inter-group analysis ( Table 2) . The liver enzymes, asparigine aminotransferase and alanine aminotransferase, underwent neither intra-nor inter-group differences during the follow-up (Table 2) . However, the enzyme ã-glutamyltransferase underwent a significant intra-group reduction in both groups, but no inter-group differences were detected ( Table 2) .
Regarding the inflammatory parameters, both Gly/Gly and Gly/Ser þ Ser/Ser groups showed significant reductions of us-CRP, fibrinogen, MCP-1 and IL-6 ( Table 3) . The blood leukocyte counts dropped significantly only in the Gly/Ser þ Ser/Ser group (Table 3 ). Significant inter-group differences, as evaluated by the Mann-Whitney test, were detected for us-CRP and blood leukocyte counts (Table 3) , while significant differences between the means of variations during the 12-month follow-up were detected for blood leukocyte counts (Figure 1c ) and IL-6 (Figure 1d) .
In addition to the anthropometric, metabolic, biochemical and inflammatory parameters, we employed Doppler ultrasonography to determine the C-IMT. Both Gly/Gly and Gly/Ser þ Ser/Ser patients had significant reductions of the IMT during the 12-month follow-up (Figure 1e ). However, upon comparison of the means of reductions, a significantly greater reduction was observed in the Gly/Ser þ Ser/Ser group (Figure 1e, inset) .
Discussion
The function of PGC1a as a transcriptional regulator of a number of proteins involved in metabolism has placed this protein and its encoding gene as causal candidates in the pathogenesis of diabetes and related diseases. 6 In a recent meta-analysis, the most common ppargc1a gene polymorphism, Gly482Ser, was associated with an increased risk for type 2 diabetes. 8 However, there are studies suggesting a neutral or protective role for this polymorphism in obesity, metabolic and cardiovascular diseases. [11] [12] [13] Thus, further work is required to provide a more in-depth view of the role of this polymorphism in human health and disease. As a rather prevalent polymorphism, ranging from 20 to 50% in distinct populations, 8, 9 the Gly482Ser may be an interesting marker for disease progression and complications, and for the association between distinct diseases or clinical conditions. With the recent increase in the number of obese patients selected for gastric bypass surgery, we asked PGC1a polymorphism in obesity SR Geloneze et al whether the presence of the Gly482Ser polymorphism of the ppargc1a gene would predict different outcomes for a number of anthropometric, metabolic, inflammatory and cardiovascular parameters. At baseline, both the groups were perfectly matched for all the parameters that were evaluated. Importantly, after the 12-month follow-up, the reduction in body mass index was similar between the groups, and thus, all the significant differences detected in this study occurred independently of body mass variation. In addition, because of differences in gender distribution, we also tested men and women separately to assure that the differences found are independent of gender, and indeed, all findings remained similar after sorting out by gender. The waist/hip ratio was the only anthropometric parameter that underwent a significantly different reduction between the groups 12 months after the surgery. Patients of the Gly/Ser þ Ser/Ser group had a non-significantly higher waist/hip ratio at baseline and after 12 months this difference was shifted, resulting in a significantly different overtime variation. As an important marker of metabolic fitness, a greater reduction of the waist/hip ratio is an interesting outcome of the surgical procedure.
14 Although the measurement of waist/hip ratio is very much dependent on the examiner's skills, the magnitude of the difference found between the groups (0.03 vs 0.08) reduces the chances of human error in this case. Moreover, this index is widely used in the evaluation of obese subjects, and is frequently found to correlate very well with a number of metabolic and inflammatory parameters. 15 Regarding the metabolic and biochemical parameters evaluated, glucose was the only one that underwent a significantly greater reduction in the Gly/Ser þ Ser/Ser group. Although none of the remaining parameters related to glucose homeostasis underwent significantly different variations over time, it is clear that the mean levels of insulin, homeostatic model assessment-insulin resistance and leptin, which were higher in the Gly/Ser þ Ser/Ser group at baseline, became lower after 12 months. Thus, the overall metabolic outcome of the gastric bypass surgery is clearly superior for patients of the Gly/Ser þ Ser/Ser group.
Interestingly, three important markers of systemic inflammation, CRP, blood leukocyte counts and IL-6, underwent significantly greater reductions over time in the patients of the Gly/Ser þ Ser/Ser group. As subclinical inflammation is one of the main mechanisms involved in obesity-related insulin resistance, 16 and is present also in atherosclerosis, 17, 18 the greater reduction of systemic inflammation in the Gly/Ser þ Ser/Ser patients might have impacted on the better metabolic and vascular outcomes of this group. Finally, we evaluated the impact of gastric bypass surgery on vascular fitness, one of the most relevant targets of obesity-associated disease. Evaluation of IMT was performed by Doppler ultrasonography, a method that correlates very well with the results obtained by the direct microscopic examination of the IMT in vascular specimens. 19 A significantly higher reduction of C-IMT was observed in the Gly/Ser þ Ser/Ser patients. Whereas in the Gly/Gly group, IMT was reduced by 0.20 mm after 12 months, which is, per se, an outstanding result if compared, for example, with the outcomes of statin treatment alone, 20 in the Gly/Ser þ Ser/Ser patients the reduction reached 0.27 mm, which is, to our knowledge, one of the most relevant C-IMT reductions reported so far. 20 The recent findings of two large metaanalyses showing that IMT is indeed a strong predictor of future vascular events 20, 21 places our finding as an important difference in the outcomes of gastric bypass surgery between subjects carrying or not carrying the Gly482Ser polymorphism.
In conclusion, the presence of the Gly482Ser polymorphism may predict improved metabolic and inflammatory outcomes, ultimately leading to a more pronounced reduction in a structural marker of atherosclerosis in obese patients undergoing gastric bypass surgery. The evaluation of this polymorphism may contribute to refine the selection of candidates for this invasive procedure.
